IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
IRADIMED CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$87.65−0.62 (-0.70%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 49.0
- Dividend yield
- –
IRADIMED CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Devices: | – | – | – | – | – | – | – | – | $15.47M | $25.79M | – | – |
| Disposable IV sets and services | – | – | – | – | – | – | – | – | $7.61M | $6.71M | – | – |
| MRI Compatible Patient Vital Signs Monitoring Systems | – | – | – | – | – | – | – | – | $1.85M | $293.55K | – | – |
| "MRI Compatible Intravenous (""IV"") Infusion Pump Systems" | – | – | – | – | – | – | – | – | $13.62M | $25.49M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $70.56M | $60.61M | $52.53M | $43.90M | $33.46M | $24.54M | $30.93M | $24.51M | $19.50M | $28.90M | 84.2% | +16.4% |
| International | $13.26M | $12.64M | – | – | – | – | – | – | – | – | 15.8% | +4.9% |
| International | – | $12.64M | $13.04M | $9.40M | $8.35M | $7.18M | $7.59M | $5.93M | $3.58M | $3.59M | – | – |
| United States | – | – | – | – | – | – | – | – | $19.50M | $28.90M | – | – |
From the segment and revenue-disaggregation notes of Iradimed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.